Haleon Beheer

Beheer criteriumcontroles 1/4

De CEO Haleon's is Brian McNamara, benoemd in Jul2021, heeft een ambtstermijn van 3.25 jaar. De totale jaarlijkse vergoeding van { bedraagt £ 5.76M, bestaande uit 21.7% salaris en 78.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.014% van de aandelen van het bedrijf, ter waarde £ 4.98M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1 jaar en 2.3 jaar.

Belangrijke informatie

Brian McNamara

Algemeen directeur

UK£5.8m

Totale compensatie

Percentage CEO-salaris	21.7%
Dienstverband CEO	3.3yrs
Eigendom CEO	0.01%
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	2.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Brian McNamara's beloning veranderd ten opzichte van Haleon's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	UK£1b
Mar 31 2024	n/a	n/a	UK£1b
Dec 31 2023	UK£6m	UK£1m	UK£1b
Sep 30 2023	n/a	n/a	UK£1b
Jun 30 2023	n/a	n/a	UK£1b
Mar 31 2023	n/a	n/a	UK£1b
Dec 31 2022	UK£2m	UK£719k	UK£1b

Compensatie versus markt: De totale vergoeding ($USD 7.52M ) Brian } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 5.83M ).

Compensatie versus inkomsten: De beloning van Brian is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.

CEO

Brian McNamara (58 yo)

3.3yrs

Tenure

UK£5,763,000

Compensatie

Mr. Brian James McNamara serves as Independent Director at Mondelez International, Inc. since February 01, 2024. He serves as Chief Executive Officer at Haleon plc and serves as its Executive Director sinc...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Brian McNamara	CEO & Executive Director	3.3yrs	UK£5.76m	0.014% £ 4.7m
Tobias Hestler	CFO & Executive Director	2.8yrs	UK£2.05m	0.00072% £ 244.2k
Claire Dickson	Chief Digital & Technology Officer	less than a year	geen gegevens	geen gegevens
Sonya Ghobrial	Head of Investor Relations	no data	geen gegevens	geen gegevens
Adrian Morris	General Counsel	less than a year	geen gegevens	geen gegevens
Tamara Rogers	Chief Marketing Officer	2.8yrs	geen gegevens	0.00032% £ 108.5k
Line De Decker	Chief Human Resources Officer	less than a year	geen gegevens	geen gegevens
Filippo Lanzi	President of EMEA & LatAm	no data	geen gegevens	0.00076% £ 257.7k
Keith Choy	President of Asia Pacific	no data	geen gegevens	0.00062% £ 210.3k
Lisa Paley	President of North America	no data	geen gegevens	0.00043% £ 145.8k
Franck Riot	Chief R&D Officer	no data	geen gegevens	0.00024% £ 81.4k
Bjorn Timelin	Head of Strategy	less than a year	geen gegevens	geen gegevens

1.0yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van HLNL wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Brian McNamara	CEO & Executive Director	2.4yrs	UK£5.76m	0.014% £ 4.7m
Tobias Hestler	CFO & Executive Director	2.4yrs	UK£2.05m	0.00072% £ 244.2k
Dame Cox	Independent Non-Executive Director	2.3yrs	UK£125.40k	geen gegevens
Manvinder Banga	Senior Independent Non-Executive Director	2.3yrs	UK£145.60k	0.0036% £ 1.2m
Tracy Clarke	Independent Non-Executive Director	2.3yrs	UK£135.20k	0.00014% £ 47.5k
Alan James Stewart	Independent Non-Executive Director	less than a year	geen gegevens	geen gegevens
David Lewis	Independent Non-Executive Chair	2.4yrs	UK£705.60k	0.0010% £ 356.1k
David Denton	Non-Executive Director	1.6yrs	UK£200.00	geen gegevens
Bryan Supran	Non-Executive Director	2.3yrs	UK£6.10k	0.00055% £ 186.5k
Nancy Avila	Independent Non-Executive Director	less than a year	geen gegevens	geen gegevens
Marie-Anne Aymerich	Independent Non-Executive Director	2.3yrs	UK£123.00k	0.00031% £ 105.1k
Asmita Dubey	Independent Non-Executive Director	2.3yrs	UK£96.80k	geen gegevens

2.3yrs

Gemiddelde duur

58.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van HLNL wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.3 jaar), wat duidt op een nieuw bestuur.

Haleon Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Haleon plc Announces Directorate Change

Haleon plc Announces Chief Financial Officer Changes

Haleon plc, Annual General Meeting, May 08, 2024

High number of new and inexperienced directors

Independent Non-Executive Chair recently bought UK£100k worth of stock

Haleon plc Announces Board Changes

Recent updates

Haleon plc (LSE:HLN) commences an Equity Buyback Plan for 455,701,825 shares, representing 4.99% of its issued share capital., under the authorization approved on May 8, 2024.

Pfizer Intends to Sell About 540 Million Ordinary Shares in Haleon

Dr. Reddy'S Laboratories S.A. completed the acquisition of Northstar Switzerland SARL from Haleon plc (LSE:HLN).

Haleon Announces the Launch of Eroxon®?, the First and Only Fda Cleared Otc Gel for Erectile Dysfunction, Available for U.S. Pre Order Without A Prescription

Haleon plc (LSE:HLN) commences an Equity Buyback Plan for 913,000,000 shares, representing 10% of its issued share capital, under the authorization approved on May 8, 2024.

Haleon plc (LSE:HLN) commences an Equity Buyback Plan for 913,000,000 shares, representing 10% of its issued share capital, under the authorization approved on May 8, 2024.

Haleon plc Provides Earnings Guidance for the Fiscal Year 2024

Haleon plc to Report Fiscal Year 2024 Results on Mar 05, 2025

Dr. Reddy'S Laboratories S.A. signed a definitive agreement to acquire Northstar Switzerland SARL from Haleon plc (LSE:HLN) for £500 million.

GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon

First quarter 2024 earnings released: EPS: UK£0.046 (vs UK£0.042 in 1Q 2023)

Haleon plc Announces Directorate Change

Now 20% overvalued after recent price rise

Haleon plc Announces Chief Financial Officer Changes

Haleon plc has completed a Follow-on Equity Offering in the amount of $3.1 billion.

Haleon plc has filed a Follow-on Equity Offering.

Haleon plc has filed a Follow-on Equity Offering.

Sensodyne Introduces New Triple Action Formula: 'Sensitivity Gum & Enamel'

Upcoming dividend of UK£0.042 per share

Final dividend increased to UK£0.042

Full year 2023 earnings released: EPS: UK£0.11 (vs UK£0.12 in FY 2022)

Haleon plc, Annual General Meeting, May 08, 2024

Now 23% overvalued

Haleon plc Proposes Final Dividend for Fiscal Year 2023, Payable on 16 May 2024

Dr Reddy's Laboratories Reportedly Eyes Mega Brand in UK

Third quarter 2023 earnings released: EPS: UK£0.04 (vs UK£0.037 in 3Q 2022)

Haleon plc to Report Fiscal Year 2023 Results on Feb 29, 2024

An unknown buyer acquired a 2.923787% stake in Haleon plc from GSK plc for approximately £890 million.

An unknown buyer acquired a 2.923787% stake in Haleon plc from GSK plc for approximately £890 million.

Upcoming dividend of UK£0.018 per share at 1.1% yield

Second quarter 2023 earnings released: EPS: UK£0.032 (vs UK£0.019 in 2Q 2022)

Haleon plc Provides Earnings Guidance for the Fiscal Year 2023

Haleon Reportedly Exploring Sale of Nicotine Gum Business

First quarter 2023 earnings released: EPS: UK£0.042 (vs UK£0.037 in 1Q 2022)

High number of new and inexperienced directors

Independent Non-Executive Chair recently bought UK£100k worth of stock

Full year 2022 earnings released: EPS: UK£0.12 (vs UK£0.15 in FY 2021)

Haleon plc Announces Board Changes

Third quarter 2022 earnings released

Haleon plc Provides Revenue Guidance for Fiscal 2022

Second quarter 2022 earnings released

Haleon plc Provides Revenue Guidance for Fiscal 2022

Haleon Introduces Advil PLUS Acetaminophen to Canadians, Combining Two Trusted Pain Relievers into One Convenient Tablet

Haleon plc to Report First Half, 2022 Results on Sep 19, 2022

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd